These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28793061)

  • 21. Advancing a Human Rights-Based Approach to Access to Medicines: Lessons Learned from the Constitutional Court of Peru.
    Davies L
    Health Hum Rights; 2022 Jun; 24(1):49-58. PubMed ID: 35747285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stakeholders' perspectives on access-to-medicines policy and research priorities in Latin America and the Caribbean: face-to-face and web-based interviews.
    Azeredo TB; Luiza VL; Oliveira MA; Emmerick IC; Bigdeli M
    Health Res Policy Syst; 2014 Jun; 12():31. PubMed ID: 24965383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B
    Pharm Pat Anal; 2012 Nov; 1(5):555-75. PubMed ID: 24236925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis.
    McMullan P; Ajay VS; Srinivas R; Bhalla S; Prabhakaran D; Banerjee A
    Glob Health Action; 2018; 11(1):1434935. PubMed ID: 29495950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines.
    Ruxin J; Paluzzi JE; Wilson PA; Tozan Yi; Kruk M; Teklehaimanot A
    Lancet; 2005 Feb 12-18; 365(9459):618-21. PubMed ID: 15708108
    [No Abstract]   [Full Text] [Related]  

  • 26. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are drug companies living up to their human rights responsibilities? The perspective of the former United Nations Special Rapporteur (2002-2008).
    Hunt P; Khosla R
    PLoS Med; 2010 Sep; 7(9):e1000330. PubMed ID: 20927413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Access to innovative medicines by pharma companies: Sustainable initiatives for global health or useful advertisement?
    Rocha MM; de Andrade EP; Alves ER; Cândido JC; Borio MM
    Glob Public Health; 2020 Jun; 15(6):777-789. PubMed ID: 32070242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supply chain management of health commodities for reducing global disease burden.
    Chukwu OA; Ezeanochikwa VN; Eya BE
    Res Social Adm Pharm; 2017; 13(4):871-874. PubMed ID: 27720436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction: Pharmaceutical firms and the right to health.
    de Campos TC; Pogge T
    J Law Med Ethics; 2012; 40(2):183-7. PubMed ID: 22789038
    [No Abstract]   [Full Text] [Related]  

  • 31. Applying human rights to improve access to reproductive health services.
    Shaw D; Cook RJ
    Int J Gynaecol Obstet; 2012 Oct; 119 Suppl 1():S55-9. PubMed ID: 22883913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. UN urges broader access to drugs.
    Gulland A
    BMJ; 2016 Sep; 354():i5017. PubMed ID: 27634303
    [No Abstract]   [Full Text] [Related]  

  • 33. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
    Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
    PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The regulation and adoption of health technologies under Brazil's Unified Health System: barriers to access to medicines for diseases of poverty?
    Santana RS; Lupatini EO; Leite SN
    Cien Saude Colet; 2017 May; 22(5):1417-1428. PubMed ID: 28538914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. UK Commission concludes international patent laws hinder access to medicines in developing countries.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):59. PubMed ID: 14740605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. World report on disability.
    Shakespeare T; Officer A
    Disabil Rehabil; 2011; 33(17-18):1491. PubMed ID: 21780912
    [No Abstract]   [Full Text] [Related]  

  • 37. Medicines in Mexico, 1990-2004: systematic review of research on access and use.
    Wirtz VJ; Reich MR; Leyva Flores R; Dreser A
    Salud Publica Mex; 2008; 50 Suppl 4():S470-9. PubMed ID: 19082258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alternatives for adopting policies centered on access to medicines].
    Tobar F; Drake I; Martich E
    Rev Panam Salud Publica; 2012 Dec; 32(6):457-63. PubMed ID: 23370190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 40. On the Policy of the Italian Government in the Discovery, Development, and Access to Medicines.
    Scavone C; Carnovale C; Ruggiero R; Radice S; Scatigna M; Racagni G; Mugelli A; Rossi F; Clementi E; Capuano A
    Clin Ther; 2018 Nov; 40(11):1931-1940. PubMed ID: 30458933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.